These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 26253538)

  • 1. Glucagon-like peptide-1 protects against ischemic left ventricular dysfunction during hyperglycemia in patients with coronary artery disease and type 2 diabetes mellitus.
    McCormick LM; Heck PM; Ring LS; Kydd AC; Clarke SJ; Hoole SP; Dutka DP
    Cardiovasc Diabetol; 2015 Aug; 14():102. PubMed ID: 26253538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic dipeptidyl peptidase-4 inhibition with sitagliptin is associated with sustained protection against ischemic left ventricular dysfunction in a pilot study of patients with type 2 diabetes mellitus and coronary artery disease.
    McCormick LM; Kydd AC; Read PA; Ring LS; Bond SJ; Hoole SP; Dutka DP
    Circ Cardiovasc Imaging; 2014 Mar; 7(2):274-81. PubMed ID: 24503784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardioprotection against ischaemia induced by dobutamine stress using glucagon-like peptide-1 in patients with coronary artery disease.
    Read PA; Khan FZ; Dutka DP
    Heart; 2012 Mar; 98(5):408-13. PubMed ID: 21561896
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease.
    Read PA; Khan FZ; Heck PM; Hoole SP; Dutka DP
    Circ Cardiovasc Imaging; 2010 Mar; 3(2):195-201. PubMed ID: 20075143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes.
    Lambadiari V; Pavlidis G; Kousathana F; Varoudi M; Vlastos D; Maratou E; Georgiou D; Andreadou I; Parissis J; Triantafyllidi H; Lekakis J; Iliodromitis E; Dimitriadis G; Ikonomidis I
    Cardiovasc Diabetol; 2018 Jan; 17(1):8. PubMed ID: 29310645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of glycemic control on aortic stiffness, left ventricular mass and diastolic longitudinal function in type 2 diabetes mellitus.
    Kozakova M; Morizzo C; Fraser AG; Palombo C
    Cardiovasc Diabetol; 2017 Jun; 16(1):78. PubMed ID: 28623932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study.
    Kumarathurai P; Anholm C; Nielsen OW; Kristiansen OP; Mølvig J; Madsbad S; Haugaard SB; Sajadieh A
    Cardiovasc Diabetol; 2016 Jul; 15(1):105. PubMed ID: 27455835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of exenatide on cardiac function, perfusion, and energetics in type 2 diabetic patients with cardiomyopathy: a randomized controlled trial against insulin glargine.
    Chen WJY; Diamant M; de Boer K; Harms HJ; Robbers LFHJ; van Rossum AC; Kramer MHH; Lammertsma AA; Knaapen P
    Cardiovasc Diabetol; 2017 May; 16(1):67. PubMed ID: 28526033
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hyperinsulinemia improves ischemic LV function in insulin resistant subjects.
    Heck PM; Hoole SP; Khan SN; Dutka DP
    Cardiovasc Diabetol; 2010 Jun; 9():27. PubMed ID: 20576156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pre-treatment with glucagon-like Peptide-1 protects against ischemic left ventricular dysfunction and stunning without a detected difference in myocardial substrate utilization.
    McCormick LM; Hoole SP; White PA; Read PA; Axell RG; Clarke SJ; O'Sullivan M; West NEJ; Dutka DP
    JACC Cardiovasc Interv; 2015 Feb; 8(2):292-301. PubMed ID: 25700752
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coronary microvascular function is independently associated with left ventricular filling pressure in patients with type 2 diabetes mellitus.
    Kawata T; Daimon M; Miyazaki S; Ichikawa R; Maruyama M; Chiang SJ; Ito C; Sato F; Watada H; Daida H
    Cardiovasc Diabetol; 2015 Aug; 14():98. PubMed ID: 26242308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study to assess whether glucagon-like peptide-1 protects the heart from ischemic dysfunction and attenuates stunning after coronary balloon occlusion in humans.
    Read PA; Hoole SP; White PA; Khan FZ; O'Sullivan M; West NE; Dutka DP
    Circ Cardiovasc Interv; 2011 Jun; 4(3):266-72. PubMed ID: 21586690
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion.
    Nikolaidis LA; Mankad S; Sokos GG; Miske G; Shah A; Elahi D; Shannon RP
    Circulation; 2004 Mar; 109(8):962-5. PubMed ID: 14981009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy.
    Nikolaidis LA; Elahi D; Shen YT; Shannon RP
    Am J Physiol Heart Circ Physiol; 2005 Dec; 289(6):H2401-8. PubMed ID: 16024574
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical features of subclinical left ventricular systolic dysfunction in patients with diabetes mellitus.
    Mochizuki Y; Tanaka H; Matsumoto K; Sano H; Toki H; Shimoura H; Ooka J; Sawa T; Motoji Y; Ryo K; Hirota Y; Ogawa W; Hirata K
    Cardiovasc Diabetol; 2015 Apr; 14():37. PubMed ID: 25889250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of acute hyperglycemia on layer-specific left ventricular strain in asymptomatic diabetic patients: an analysis based on two-dimensional speckle tracking echocardiography.
    Bogdanović J; Ašanin M; Krljanac G; Lalić NM; Jotić A; Stanković S; Rajković N; Stošić L; Rasulić I; Milin J; Popović D; Bogdanović L; Lalić K
    Cardiovasc Diabetol; 2019 Jun; 18(1):68. PubMed ID: 31159858
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy.
    Nikolaidis LA; Elahi D; Hentosz T; Doverspike A; Huerbin R; Zourelias L; Stolarski C; Shen YT; Shannon RP
    Circulation; 2004 Aug; 110(8):955-61. PubMed ID: 15313949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of cardiac autonomic neuropathy with subclinical myocardial dysfunction in type 2 diabetes.
    Sacre JW; Franjic B; Jellis CL; Jenkins C; Coombes JS; Marwick TH
    JACC Cardiovasc Imaging; 2010 Dec; 3(12):1207-15. PubMed ID: 21163448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a definite diabetic cardiomyopathy in type 2 diabetes by comprehensive echocardiographic evaluation: A cross-sectional comparison with non-diabetic weight-matched controls.
    Ofstad AP; Urheim S; Dalen H; Orvik E; Birkeland KI; Gullestad L; W Fagerland M; Johansen OE; Aakhus S
    J Diabetes; 2015 Nov; 7(6):779-90. PubMed ID: 25350248
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sitagliptin improved glucose assimilation in detriment of fatty-acid utilization in experimental type-II diabetes: role of GLP-1 isoforms in Glut4 receptor trafficking.
    Ramírez E; Picatoste B; González-Bris A; Oteo M; Cruz F; Caro-Vadillo A; Egido J; Tuñón J; Morcillo MA; Lorenzo Ó
    Cardiovasc Diabetol; 2018 Jan; 17(1):12. PubMed ID: 29325553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.